Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136

1.

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; EXAMINE Investigators.

N Engl J Med. 2013 Oct 3;369(14):1327-35. doi: 10.1056/NEJMoa1305889. Epub 2013 Sep 2.

2.

EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome.

White WB, Bakris GL, Bergenstal RM, Cannon CP, Cushman WC, Fleck P, Heller S, Mehta C, Nissen SE, Perez A, Wilson C, Zannad F.

Am Heart J. 2011 Oct;162(4):620-626.e1. doi: 10.1016/j.ahj.2011.08.004. Epub 2011 Sep 14.

PMID:
21982652
3.

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.

Zannad F, Cannon CP, Cushman WC, Bakris GL, Menon V, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Lam H, White WB; EXAMINE Investigators.

Lancet. 2015 May 23;385(9982):2067-76. doi: 10.1016/S0140-6736(14)62225-X. Epub 2015 Mar 10.

PMID:
25765696
4.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 009 Group.

Curr Med Res Opin. 2009 Oct;25(10):2361-71. doi: 10.1185/03007990903156111.

PMID:
19650752
5.

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I; SAVOR-TIMI 53 Steering Committee and Investigators.

N Engl J Med. 2013 Oct 3;369(14):1317-26. doi: 10.1056/NEJMoa1307684. Epub 2013 Sep 2.

6.

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.

White WB, Pratley R, Fleck P, Munsaka M, Hisada M, Wilson C, Menon V.

Diabetes Obes Metab. 2013 Jul;15(7):668-73. doi: 10.1111/dom.12093. Epub 2013 Apr 4.

PMID:
23489301
7.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.

Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q; Alogliptin Study 007 Group.

Diabetes Obes Metab. 2009 Feb;11(2):167-76. doi: 10.1111/j.1463-1326.2008.01016.x.

PMID:
19125778
8.

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.

Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q.

J Am Geriatr Soc. 2009 Nov;57(11):2011-9. doi: 10.1111/j.1532-5415.2009.02484.x. Epub 2009 Sep 30.

PMID:
19793357
9.

Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.

Del Prato S, Camisasca R, Wilson C, Fleck P.

Diabetes Obes Metab. 2014 Dec;16(12):1239-46. doi: 10.1111/dom.12377. Epub 2014 Sep 25.

PMID:
25132212
10.

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.

Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators.

N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.

PMID:
26630143
11.

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy--focus on alogliptin.

Capuano A, Sportiello L, Maiorino MI, Rossi F, Giugliano D, Esposito K.

Drug Des Devel Ther. 2013 Sep 17;7:989-1001. doi: 10.2147/DDDT.S37647. eCollection 2013. Review.

12.

Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.

Rosenstock J, Wilson C, Fleck P.

Diabetes Obes Metab. 2013 Oct;15(10):906-14. doi: 10.1111/dom.12102. Epub 2013 Apr 18.

PMID:
23531118
13.

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.

Fujii Y, Abe M, Higuchi T, Mizuno M, Suzuki H, Matsumoto S, Ito M, Maruyama N, Okada K, Soma M.

Expert Opin Pharmacother. 2013 Feb;14(3):259-67. doi: 10.1517/14656566.2013.761690. Epub 2013 Jan 7.

PMID:
23289982
14.

Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.

Jarvis CI, Cabrera A, Charron D.

Ann Pharmacother. 2013 Nov;47(11):1532-9. doi: 10.1177/1060028013504076. Review.

PMID:
24285765
15.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study.

DeFronzo RA, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 010 Group.

Diabetes Care. 2008 Dec;31(12):2315-7. doi: 10.2337/dc08-1035. Epub 2008 Sep 22.

17.

Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus.

Ndefo UA, Okoli O, Erowele G.

Am J Health Syst Pharm. 2014 Jan 15;71(2):103-9. doi: 10.2146/ajhp130131. Review.

PMID:
24375601
18.

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes.

Covington P, Christopher R, Davenport M, Fleck P, Mekki QA, Wann ER, Karim A.

Clin Ther. 2008 Mar;30(3):499-512. doi: 10.1016/j.clinthera.2008.03.004.

PMID:
18405788
19.

Saxagliptin, alogliptin, and cardiovascular outcomes.

White WB, Zannad F.

N Engl J Med. 2014 Jan 30;370(5):484. No abstract available.

PMID:
24482824
20.

Saxagliptin, alogliptin, and cardiovascular outcomes.

Standl E.

N Engl J Med. 2014 Jan 30;370(5):483. doi: 10.1056/NEJMc1313880#SA1. No abstract available.

PMID:
24476445
Items per page

Supplemental Content

Write to the Help Desk